Stock data
TransCode Therapeutics, Inc. (RNAZ)
TransCode Therapeutics, Inc. (RNAZ) reported net income of -US$34.66M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$27.98M | -US$34.66M | — |
| 2024 | — | — | -US$15.66M | -US$16.75M | — |
| 2023 | — | — | -US$19.42M | -US$18.55M | — |
| 2022 | — | — | -US$18.63M | -US$17.56M | — |
| 2021 | — | — | -US$6.15M | -US$6.84M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$6.75M | — |
| 2026-03-31 | — | -US$17.79M | — |
| 2025-12-31 | — | -US$13.44M | — |
| 2025-09-30 | — | -US$4.86M | — |
| 2025-06-30 | — | -US$4.28M | — |
| 2025-03-31 | — | -US$12.09M | — |
| 2024-12-31 | — | -US$5.92M | — |
| 2024-09-30 | — | -US$2.32M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.